Cogent Biosciences, Inc.

NasdaqGS COGT

Cogent Biosciences, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -4,672.44%

Cogent Biosciences, Inc. EBIT Margin is -4,672.44% for the Trailing 12 Months (TTM) ending September 30, 2024. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Cogent Biosciences, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -779,659,509,592,173.62%, a -836,203,148,364,886.25% change year over year.
Cogent Biosciences, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -93.24%, a 76.22% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NasdaqGS: COGT

Cogent Biosciences, Inc.

CEO	Mr. Andrew R. Robbins M.B.A.
IPO Date	March 29, 2018
Location	United States
Headquarters	200 Cambridge Park Drive
Employees	164
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years